Company: ACBM
Filing Date: 2025-07-24
Form Type: 10-K
Source: 0001640334-25-001300
Chunk: 152

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-24
Form: 10-K
Item: Item 16
Chunk 152
---
., LTD.

Statements of Operations

  Year ended   December 31,   2024  2023        Revenues $-  $-          Operating expenses        Selling, general and administrative  37,958   3,517,542 Research and development  -   4,794,825 Provision for doubtful accounts  -   480,000 Provision for purchase deposit write-off  -   12,000 Total operating expenses  37,958   8,804,367          Loss from operations  (37,958)  (8,804,367)         Other expense        Interest expense - related parties  4,339   3,206 Total other expenses  4,339   3,206          Loss before income tax expense  (42,297)  (8,807,573)Income tax expense  -   - Net loss $(42,297) $(8,807,573)         Basic and diluted loss per share of common stock $(0.00) $(0.15)         Weighted average number of shares of common stock outstanding  60,042,000   60,042,000 

The accompanying notes are an integral part of these financial statements.

 F-4Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Changes in Stockholders’ Equity (Deficit)

               Additional   Deferred     Total   Preferred Stock  Common Stock   Paid in    stock  Accumulated  Stockholders’     Shares    Amount    Shares    Amount    Capital   compensation   Deficit  Equity (Deficit)                          Balance, December 31, 2022  -  $-   60,042,000  $60,042  $32,295,236  $(8,060,983) $(23,807,925) $486,370                                  Amortization of deferred stock compensation   -   -   -   -   -   8,060,983   -   8,060,983 Imputed interest on related